Global Diabetes Market Research and Analysis, 2014-2020
Market Insight
Global Diabetes Market is expected to grow at a CAGR of 8.1 percent for the forecasted period of 2015-2020. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 9.2%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate. Diabetic drugs are highly priced which could be one of the major drawbacks.
Diabetic devices includes blood glucose meters and insulin delivery devices. The market for blood glucose meters will have the highest market share compared to the insulin delivery systems such as syringes and injection pens. Continuous glucose monitoring systems will have the highest market growth. Meter and strips are expected to dominate the overall market share in diabetic devices.
Overall the market is driven by growing burden of diabetes on economies. U.S. alone spends 11% of its health expenditure on diabetes. India and China are most affected by diabetes with over 120 million patients. A majority of diabetes patients are either undiagnosed or lack the basic treatment. The impending unmet needs are forcing the companies and governments to provide basic needs for diabetes. Research and development is ongoing to development long term solution for diabetes. Some of the leading manufacturers are trying to develop artificial pancreas. Currently CGMS devices are being used with insulin pumps as secondary prototype for artificial pancreas. It is expected that artificial pancreas will be ready for commercialization by next decade. Development of artificial pancreas has gained support from USFDA, which is a major boost for the market.
North America is the leading geography followed by Europe and Asia Pacific. Asia Pacific is expected to have the highest growth rate amongst the regions. North American market is driven by high awareness, availability of reimbursements and high expenditure on healthcare. Asia Pacific market is driven by high population of diabetic patients.
Global Diabetes Market is expected to grow at a CAGR of 8.1 percent for the forecasted period of 2015-2020. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 9.2%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate. Diabetic drugs are highly priced which could be one of the major drawbacks.
Diabetic devices includes blood glucose meters and insulin delivery devices. The market for blood glucose meters will have the highest market share compared to the insulin delivery systems such as syringes and injection pens. Continuous glucose monitoring systems will have the highest market growth. Meter and strips are expected to dominate the overall market share in diabetic devices.
Overall the market is driven by growing burden of diabetes on economies. U.S. alone spends 11% of its health expenditure on diabetes. India and China are most affected by diabetes with over 120 million patients. A majority of diabetes patients are either undiagnosed or lack the basic treatment. The impending unmet needs are forcing the companies and governments to provide basic needs for diabetes. Research and development is ongoing to development long term solution for diabetes. Some of the leading manufacturers are trying to develop artificial pancreas. Currently CGMS devices are being used with insulin pumps as secondary prototype for artificial pancreas. It is expected that artificial pancreas will be ready for commercialization by next decade. Development of artificial pancreas has gained support from USFDA, which is a major boost for the market.
North America is the leading geography followed by Europe and Asia Pacific. Asia Pacific is expected to have the highest growth rate amongst the regions. North American market is driven by high awareness, availability of reimbursements and high expenditure on healthcare. Asia Pacific market is driven by high population of diabetic patients.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. ANALYST INSIGHT
2.5.1. KEY FINDINGS
2.5.2. RECOMMENDATION
2.5.3. CONCLUSION
2.6. REGULATION
2.6.1. TAX LAWS
2.6.1.1. UNITED STATES
2.6.1.2. EUROPEAN UNION
2.6.1.3. CHINA
2.6.1.4. INDIA
2.6.1.5. REST OF THE WORLD
2.6.2. DRUG AND DEVICE REGULATIONS
2.6.2.1. UNITED STATES
2.6.2.2. EUROPEAN UNION
2.6.2.3. CHINA
2.6.2.4. INDIA
2.6.2.5. REST OF THE WORLD
2.7. TOP 10 SELLING DIABETES DRUGS
2.7.1. LANTUS (SANOFI)
2.7.2. JANUVIA (MERCK AND CO)
2.7.3. HUMALOG (ELI LILY AND CO)
2.7.4. NOVORAPID (NOVO NORDISK)
2.7.5. LEVEMIR (NOVO NORDISK)
2.7.6. VICTOZA (NOVO NORDISK)
2.7.7. JANUMET (MERCK AND CO.)
2.7.8. NOVOLOG (NOVO NORDISK)
2.7.9. HUMALIN (ELI LILY AND CO.)
2.7.10. GALVUS (NOVARTIS)
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING PREVALENCE AND INCIDENCE RATE OF DIABETES
3.1.2. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
3.1.3. GROWING POPULARITY OF WEARABLE DEVICES AND POC SOLUTIONS
3.2. RESTRAINT
3.2.1. NUMBER OF UNDIAGNOSED PATIENTS IN DEVELOPING COUNTRIES IS HIGH
3.2.2. CGMS AND INSULIN PUMPS DEVICES SALE LIMITED TO DEVELOPED MARKET
3.2.3. HIGH PRICE AND RECURRING COST
3.3. OPPORTUNITY
3.3.1. EMERGING MARKETS
3.3.2. DEVELOPMENT OF ARTIFICIAL PANCREASES
3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON-INVASIVE MONITORING DEVICES
DIABETIC DRUGS AND DEVICES-@PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL DIABETES MARKET BY TYPE MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.1. GLOBAL TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.2. GLOBAL TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.3. GLOBAL GESTATIONAL DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2. GLOBAL DRUG CLASS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1. GLOBAL ALPHA-GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2. GLOBAL AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3. GLOBAL ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4. GLOBAL DIPEPTIDYL PEPTIDASE 4 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5. GLOBAL INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.6. GLOBAL INSULIN MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.7. GLOBAL MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.8. GLOBAL NON-SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.9. GLOBAL SGLT-2 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.10. GLOBAL SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.11. GLOBAL THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3. GLOBAL DIABETIC DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.1. GLOBAL BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.2. GLOBAL BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.3. GLOBAL INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.4. GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.5. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.6. GLOBAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.7. GLOBAL LANCETS MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. NOVO NORDISK
8.1.1. INTRODUCTION
8.1.2. PRODUCT PORTFOLIO
8.1.3. RECENT ACTIVITIES
8.1.4. SWOT
8.2. SANOFI
8.2.1. INTRODUCTION
8.2.2. PRODUCT PORTFOLIO
8.2.3. RECENT ACTIVITIES
8.2.4. SWOT
8.3. MERCK AND CO.
8.3.1. INTRODUCTION
8.3.2. PRODUCT PORTFOLIO
8.3.3. RECENT ACTIVITIES
8.3.4. SWOT
8.4. ELI LILY AND CO.
8.4.1. INTRODUCTION
8.4.2. PRODUCT PORTFOLIO
8.4.3. RECENT ACTIVITIES
8.4.4. SWOT
8.5. ASTRAZENECA
8.5.1. INTRODUCTION
8.5.2. PRODUCT PORTFOLIO
8.5.3. RECENT ACTIVITIES
8.5.4. SWOT
8.6. BOEHRINGER INGELHEIM
8.6.1. INTRODUCTION
8.6.2. PRODUCT PORTFOLIO
8.6.3. RECENT ACTIVITIES
8.6.4. SWOT
8.7. JOHNSON AND JOHNSON
8.7.1. INTRODUCTION
8.7.2. PRODUCT PORTFOLIO
8.7.3. RECENT ACTIVITIES
8.7.4. SWOT
8.8. NOVARTIS
8.8.1. INTRODUCTION
8.8.2. PRODUCT PORTFOLIO
8.8.3. RECENT ACTIVITIES
8.8.4. SWOT
8.9. TAKEDA
8.9.1. INTRODUCTION
8.9.2. PRODUCT PORTFOLIO
8.9.3. RECENT ACTIVITIES
8.9.4. SWOT
8.10. MERCK KGAA
8.10.1. INTRODUCTION
8.10.2. PRODUCT PORTFOLIO
8.10.3. RECENT ACTIVITIES
8.10.4. SWOT
8.11. MEDTRONIC INC.
8.11.1. INTRODUCTION
8.11.2. PRODUCT PORTFOLIO
8.11.3. RECENT ACTIVITIES
8.11.4. SWOT
8.12. DEXCOM INC.
8.12.1. INTRODUCTION
8.12.2. PRODUCT PORTFOLIO
8.12.3. RECENT ACTIVITIES
8.12.4. SWOT
8.13. TANDEM DIABETES CARE
8.13.1. INTRODUCTION
8.13.2. PRODUCT PORTFOLIO
8.13.3. RECENT ACTIVITIES
8.13.4. SWOT
8.14. BECTON, DICKINSON AND COMPANY
8.14.1. INTRODUCTION
8.14.2. PRODUCT PORTFOLIO
8.14.3. RECENT ACTIVITIES
8.14.4. SWOT
8.15. ABBOTT LABORATORIES
8.15.1. INTRODUCTION
8.15.2. PRODUCT PORTFOLIO
8.15.3. RECENT ACTIVITIES
8.15.4. SWOT
8.16. BAYER PHARMACEUTICALS PVT. LTD.
8.16.1. INTRODUCTION
8.16.2. PRODUCT PORTFOLIO
8.16.3. RECENT ACTIVITIES
8.16.4. SWOT
8.17. F. HOFFMANN-LA ROCHE LTD.
8.17.1. INTRODUCTION
8.17.2. PRODUCT PORTFOLIO
8.17.3. RECENT ACTIVITIES
8.17.4. SWOT
8.18. ALERE INC.
8.18.1. INTRODUCTION
8.18.2. PRODUCT PORTFOLIO
8.18.3. RECENT ACTIVITIES
8.18.4. SWOT
8.19. SMITHS MEDICAL
8.19.1. INTRODUCTION
8.19.2. PRODUCT PORTFOLIO
8.19.3. RECENT ACTIVITIES
8.19.4. SWOT
8.20. JOSLIN DIABETES CENTER
8.20.1. INTRODUCTION
8.20.2. PRODUCT PORTFOLIO
8.20.3. RECENT ACTIVITIES
8.20.4. SWOT
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. ANALYST INSIGHT
2.5.1. KEY FINDINGS
2.5.2. RECOMMENDATION
2.5.3. CONCLUSION
2.6. REGULATION
2.6.1. TAX LAWS
2.6.1.1. UNITED STATES
2.6.1.2. EUROPEAN UNION
2.6.1.3. CHINA
2.6.1.4. INDIA
2.6.1.5. REST OF THE WORLD
2.6.2. DRUG AND DEVICE REGULATIONS
2.6.2.1. UNITED STATES
2.6.2.2. EUROPEAN UNION
2.6.2.3. CHINA
2.6.2.4. INDIA
2.6.2.5. REST OF THE WORLD
2.7. TOP 10 SELLING DIABETES DRUGS
2.7.1. LANTUS (SANOFI)
2.7.2. JANUVIA (MERCK AND CO)
2.7.3. HUMALOG (ELI LILY AND CO)
2.7.4. NOVORAPID (NOVO NORDISK)
2.7.5. LEVEMIR (NOVO NORDISK)
2.7.6. VICTOZA (NOVO NORDISK)
2.7.7. JANUMET (MERCK AND CO.)
2.7.8. NOVOLOG (NOVO NORDISK)
2.7.9. HUMALIN (ELI LILY AND CO.)
2.7.10. GALVUS (NOVARTIS)
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING PREVALENCE AND INCIDENCE RATE OF DIABETES
3.1.2. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
3.1.3. GROWING POPULARITY OF WEARABLE DEVICES AND POC SOLUTIONS
3.2. RESTRAINT
3.2.1. NUMBER OF UNDIAGNOSED PATIENTS IN DEVELOPING COUNTRIES IS HIGH
3.2.2. CGMS AND INSULIN PUMPS DEVICES SALE LIMITED TO DEVELOPED MARKET
3.2.3. HIGH PRICE AND RECURRING COST
3.3. OPPORTUNITY
3.3.1. EMERGING MARKETS
3.3.2. DEVELOPMENT OF ARTIFICIAL PANCREASES
3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON-INVASIVE MONITORING DEVICES
DIABETIC DRUGS AND DEVICES-@PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL DIABETES MARKET BY TYPE MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.1. GLOBAL TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.2. GLOBAL TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.3. GLOBAL GESTATIONAL DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2. GLOBAL DRUG CLASS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1. GLOBAL ALPHA-GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2. GLOBAL AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3. GLOBAL ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4. GLOBAL DIPEPTIDYL PEPTIDASE 4 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5. GLOBAL INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.6. GLOBAL INSULIN MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.7. GLOBAL MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.8. GLOBAL NON-SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.9. GLOBAL SGLT-2 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.10. GLOBAL SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.11. GLOBAL THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3. GLOBAL DIABETIC DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.1. GLOBAL BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.2. GLOBAL BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.3. GLOBAL INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.4. GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.5. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.6. GLOBAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.7. GLOBAL LANCETS MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. NOVO NORDISK
8.1.1. INTRODUCTION
8.1.2. PRODUCT PORTFOLIO
8.1.3. RECENT ACTIVITIES
8.1.4. SWOT
8.2. SANOFI
8.2.1. INTRODUCTION
8.2.2. PRODUCT PORTFOLIO
8.2.3. RECENT ACTIVITIES
8.2.4. SWOT
8.3. MERCK AND CO.
8.3.1. INTRODUCTION
8.3.2. PRODUCT PORTFOLIO
8.3.3. RECENT ACTIVITIES
8.3.4. SWOT
8.4. ELI LILY AND CO.
8.4.1. INTRODUCTION
8.4.2. PRODUCT PORTFOLIO
8.4.3. RECENT ACTIVITIES
8.4.4. SWOT
8.5. ASTRAZENECA
8.5.1. INTRODUCTION
8.5.2. PRODUCT PORTFOLIO
8.5.3. RECENT ACTIVITIES
8.5.4. SWOT
8.6. BOEHRINGER INGELHEIM
8.6.1. INTRODUCTION
8.6.2. PRODUCT PORTFOLIO
8.6.3. RECENT ACTIVITIES
8.6.4. SWOT
8.7. JOHNSON AND JOHNSON
8.7.1. INTRODUCTION
8.7.2. PRODUCT PORTFOLIO
8.7.3. RECENT ACTIVITIES
8.7.4. SWOT
8.8. NOVARTIS
8.8.1. INTRODUCTION
8.8.2. PRODUCT PORTFOLIO
8.8.3. RECENT ACTIVITIES
8.8.4. SWOT
8.9. TAKEDA
8.9.1. INTRODUCTION
8.9.2. PRODUCT PORTFOLIO
8.9.3. RECENT ACTIVITIES
8.9.4. SWOT
8.10. MERCK KGAA
8.10.1. INTRODUCTION
8.10.2. PRODUCT PORTFOLIO
8.10.3. RECENT ACTIVITIES
8.10.4. SWOT
8.11. MEDTRONIC INC.
8.11.1. INTRODUCTION
8.11.2. PRODUCT PORTFOLIO
8.11.3. RECENT ACTIVITIES
8.11.4. SWOT
8.12. DEXCOM INC.
8.12.1. INTRODUCTION
8.12.2. PRODUCT PORTFOLIO
8.12.3. RECENT ACTIVITIES
8.12.4. SWOT
8.13. TANDEM DIABETES CARE
8.13.1. INTRODUCTION
8.13.2. PRODUCT PORTFOLIO
8.13.3. RECENT ACTIVITIES
8.13.4. SWOT
8.14. BECTON, DICKINSON AND COMPANY
8.14.1. INTRODUCTION
8.14.2. PRODUCT PORTFOLIO
8.14.3. RECENT ACTIVITIES
8.14.4. SWOT
8.15. ABBOTT LABORATORIES
8.15.1. INTRODUCTION
8.15.2. PRODUCT PORTFOLIO
8.15.3. RECENT ACTIVITIES
8.15.4. SWOT
8.16. BAYER PHARMACEUTICALS PVT. LTD.
8.16.1. INTRODUCTION
8.16.2. PRODUCT PORTFOLIO
8.16.3. RECENT ACTIVITIES
8.16.4. SWOT
8.17. F. HOFFMANN-LA ROCHE LTD.
8.17.1. INTRODUCTION
8.17.2. PRODUCT PORTFOLIO
8.17.3. RECENT ACTIVITIES
8.17.4. SWOT
8.18. ALERE INC.
8.18.1. INTRODUCTION
8.18.2. PRODUCT PORTFOLIO
8.18.3. RECENT ACTIVITIES
8.18.4. SWOT
8.19. SMITHS MEDICAL
8.19.1. INTRODUCTION
8.19.2. PRODUCT PORTFOLIO
8.19.3. RECENT ACTIVITIES
8.19.4. SWOT
8.20. JOSLIN DIABETES CENTER
8.20.1. INTRODUCTION
8.20.2. PRODUCT PORTFOLIO
8.20.3. RECENT ACTIVITIES
8.20.4. SWOT
LIST OF TABLES
TABLE # 1 GLOBAL DIABETES MARKET BY TYPE MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 2 GLOBAL TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 3 GLOBAL TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 4 GLOBAL GESTATIONAL DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 5 GLOBAL DRUG CLASS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 6 GLOBAL ALPHA-GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 7 GLOBAL AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 8 GLOBAL ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 9 GLOBAL DIPEPTIDYL PEPTIDASE 4 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 10 GLOBAL INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 11 GLOBAL INSULIN MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 12 GLOBAL MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 13 GLOBAL NON-SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 14 GLOBAL SGLT-2 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 15 GLOBAL SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 16 GLOBAL THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 17 GLOBAL DIABETIC DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 18 GLOBAL BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 19 GLOBAL BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 20 GLOBAL INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 21 GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 22 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 23 GLOBAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 24 GLOBAL LANCETS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 1 GLOBAL DIABETES MARKET BY TYPE MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 2 GLOBAL TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 3 GLOBAL TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 4 GLOBAL GESTATIONAL DIABETES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 5 GLOBAL DRUG CLASS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 6 GLOBAL ALPHA-GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 7 GLOBAL AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 8 GLOBAL ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 9 GLOBAL DIPEPTIDYL PEPTIDASE 4 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 10 GLOBAL INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 11 GLOBAL INSULIN MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 12 GLOBAL MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 13 GLOBAL NON-SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 14 GLOBAL SGLT-2 INHIBITORS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 15 GLOBAL SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 16 GLOBAL THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 17 GLOBAL DIABETIC DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 18 GLOBAL BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 19 GLOBAL BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 20 GLOBAL INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 21 GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 22 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 23 GLOBAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 24 GLOBAL LANCETS MARKET RESEARCH AND ANALYSIS, 2014-2020
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. NOVO NORDISK
2. SANOFI
3. MERCK AND CO.
4. ELI LILY AND CO.
5. ASTRAZENECA
6. BOEHRINGER INGELHEIM
7. JOHNSON AND JOHNSON
8. NOVARTIS
9. TAKEDA
10. MERCK KGAA
11. MEDTRONIC INC.
12. DEXCOM INC.
13. TANDEM DIABETES CARE
14. BECTON, DICKINSON AND COMPANY
15. ABBOTT LABORATORIES
16. BAYER PHARMACEUTICALS PVT. LTD.
17. F. HOFFMANN-LA ROCHE LTD.
18. ALERE INC.
19. SMITHS MEDICAL
20. JOSLIN DIABETES CENTER
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. NOVO NORDISK
2. SANOFI
3. MERCK AND CO.
4. ELI LILY AND CO.
5. ASTRAZENECA
6. BOEHRINGER INGELHEIM
7. JOHNSON AND JOHNSON
8. NOVARTIS
9. TAKEDA
10. MERCK KGAA
11. MEDTRONIC INC.
12. DEXCOM INC.
13. TANDEM DIABETES CARE
14. BECTON, DICKINSON AND COMPANY
15. ABBOTT LABORATORIES
16. BAYER PHARMACEUTICALS PVT. LTD.
17. F. HOFFMANN-LA ROCHE LTD.
18. ALERE INC.
19. SMITHS MEDICAL
20. JOSLIN DIABETES CENTER
